

## Press Release:

# From SIMPLER cohorts, Eurofins Genomics successfully extracted 38.000 samples and run 40.500 samples on GWAS microarray during a one-year period.

15<sup>th</sup> February, 2021

The work on producing genotype data for the population-based longitudinal cohorts in SIMPLER, a Swedish national research infrastructure hosted by Uppsala University, has been finalised and the project coordinator in SIMPLER describes the collaboration with Eurofins Genomics as very successful.

*“We are very happy with Eurofins’ competence and professional approach”* comments Anna-Karin Kolseth, project coordinator, SIMPLER.

The infrastructure SIMPLER consists of questionnaire data and biological samples for research on how dietary, lifestyle factors and genetics affect health, especially during the latter part of life. The work conducted by Eurofins Genomics under this project has been the DNA extraction of 38.000 saliva and blood samples, and then genotyping on microarrays, this included additional DNA samples from the SIMPLER biobank resulting in a total of 40.500 samples being genotyped. The success rate (sample to genotype) has been extremely high, above 99%. The project began in late spring 2019 and was completed on time as scheduled at the end of 2020. Genotyping was performed on the Illumina Infinium Global Screening Array (GSA MD 3.0).

SIMPLER have data extending 30 years back in time and the cohorts have been repeatedly assessed over time. Research on data from SIMPLER has and will continue to contribute insights and recommendations on diet and lifestyle choices. The additional use of molecular methods for exploring the cohorts will enhance and enable the development of new biomarkers for easier and more accurate diagnosis of chronic diseases and their precursors and to develop new individualised treatments. For more detailed information please visit [www.simpler4health.se](http://www.simpler4health.se)

Eurofins Genomics is the leading provider of genomics services in Europe and runs one of the largest commercial array facilities, utilising both Illumina and ThermoFisher Scientific (formally Affymetrix) technologies. As part of its portfolio, Eurofins Genomics also offers Next Generation Sequencing (NGS), Sanger Sequencing, oligos and microarray services. Customers benefit from product innovation developed by a dedicated R&D team and receive detailed support and analysis from the Eurofins Genomics bioinformatics department. Eurofins Genomics assists a significant variety of clients from academia to pharma. For more information please visit [www.eurofinsgenomics.com](http://www.eurofinsgenomics.com)

Please contact Anna-Karin Kolseth (project coordinator, [simpler@surgsci.uu.se](mailto:simpler@surgsci.uu.se), +46 72 9999 241) for further reference on the project.

Please contact Jeppe Skytte (Project Sales Manager – Nordics, [JeppeSkytte@eurofins.com](mailto:JeppeSkytte@eurofins.com), +45 2284 2656) for questions to Eurofins Genomics services.

**For Further Information:**

Media Contact: Julian Schlossmacher

Head of Marketing and Communications Europe

Eurofins Genomics

+49 8092 8289 925

[julianschlossmacher@eurofins.com](mailto:julianschlossmacher@eurofins.com)

Eurofins Genomics Website: [www.eurofinsgenomics.com](http://www.eurofinsgenomics.com)

**Notes to Editors:**

About Eurofins Genomics – a global leader in genomic products and services Eurofins Genomics, a member of the Eurofins Group with facilities in Europe, the United States and Asia, is an internationally leading provider of DNA sequencing services, next generation sequencing services, genotyping services, DNA synthesis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets. The company's strength is its extensive customer base and high quality services in industrial scale for the life science industries and academic research institutions around the world. For further information, please visit the [Eurofins Genomics website](http://www.eurofinsgenomics.com).

**About Eurofins – the global leader in bio-analysis**

Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agrosience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 50,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group's objective is to provide its customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world. Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).